Home > Boards > US Listed > Medical - Drugs > Stealth BioTherapeutics Corp (MITO)

Have been watching this one.

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (1) | Next 10 | Previous | Next
boston127 Member Profile
 
Followed By 84
Posts 6,946
Boards Moderated 0
Alias Born 06/17/08
160x600 placeholder
Stealth BioTherapeutics to Participate in Upcoming January Investor Conferences PR Newswire (US) - 1/7/2021 4:30:00 PM
Stealth BioTherapeutics Granted Pre-NDA Meeting For Elamipretide As A Treatment For Cardiomyopathy In Barth Syndrome PR Newswire (US) - 1/5/2021 8:00:00 PM
Stealth BioTherapeutics Announces Elamipretide Clinical Data to be Presented at the 13th International Conference on Cachexia... PR Newswire (US) - 12/9/2020 4:30:00 PM
Stealth BioTherapeutics Announces Appointment of Eve E. Slater, M.D., F.A.C.C. to its Board of Directors PR Newswire (US) - 12/7/2020 8:00:00 AM
Stealth BioTherapeutics Announces Closing of $3.2 Million Registered Direct Offering PR Newswire (US) - 11/24/2020 4:30:00 PM
Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k) Edgar (US Regulatory) - 11/23/2020 4:06:38 PM
Prospectus Filed Pursuant to Rule 424(b)(5) (424b5) Edgar (US Regulatory) - 11/20/2020 4:41:25 PM
Stealth BioTherapeutics Announces $3.2 Million Registered Direct Offering PR Newswire (US) - 11/20/2020 8:00:00 AM
Prospectus Filed Pursuant to Rule 424(b)(5) (424b5) Edgar (US Regulatory) - 11/19/2020 5:24:56 PM
Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k) Edgar (US Regulatory) - 11/19/2020 5:17:17 PM
Prospectus Filed Pursuant to Rule 424(b)(3) (424b3) Edgar (US Regulatory) - 11/9/2020 5:27:00 PM
Amended Statement of Beneficial Ownership (sc 13d/a) Edgar (US Regulatory) - 11/9/2020 4:18:36 PM
Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k) Edgar (US Regulatory) - 11/5/2020 8:06:55 AM
Stealth BioTherapeutics Reports Third Quarter 2020 Financial Results And Recent Business Highlights PR Newswire (US) - 11/5/2020 7:30:00 AM
Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k) Edgar (US Regulatory) - 11/4/2020 5:19:34 PM
Stealth BioTherapeutics Announces Development Financing To Advance Elamipretide Clinical Trials PR Newswire (US) - 11/4/2020 5:00:00 PM
Stealth BioTherapeutics to Report Third Quarter 2020 Financial Results on Thursday, November 5, 2020 PR Newswire (US) - 10/30/2020 4:30:00 PM
Stealth BioTherapeutics Announces Poster Presentation at American Society of Human Genetics (ASHG) Virtual Annual Meeting PR Newswire (US) - 10/19/2020 4:30:00 PM
Stealth BioTherapeutics Announces Poster Presentation at 2020 Annual NEALS Meeting PR Newswire (US) - 9/23/2020 4:30:00 PM
Stealth BioTherapeutics to Present at Upcoming Investor Conferences in September PR Newswire (US) - 9/10/2020 5:30:00 PM
Report of Foreign Issuer (6-k) Edgar (US Regulatory) - 8/7/2020 6:12:54 AM
Prospectus Filed Pursuant to Rule 424(b)(5) (424b5) Edgar (US Regulatory) - 8/7/2020 6:10:05 AM
Report of Foreign Issuer (6-k) Edgar (US Regulatory) - 8/6/2020 8:00:59 AM
Stealth BioTherapeutics Reports Second Quarter 2020 Financial Results and Recent Business Highlights PR Newswire (US) - 8/6/2020 7:30:00 AM
Stealth BioTherapeutics to Report Second Quarter 2020 Financial Results on Thursday, August 6, 2020 PR Newswire (US) - 7/30/2020 8:30:00 AM
boston127   Tuesday, 05/12/20 09:07:58 PM
Re: None
Post # of 7 
Have been watching this one.

Nice move today. The analysts have been all over the map with this, rating this as BUY with a price target of $14 just a few weeks ago. Last week, the price target was cut to $4.00/Share From $5.00 by H.C. Wainwright.

I am going to keep this on my radar and compose an introduction page.

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (1) | Next 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist
Consent Preferences